# Safety and Efficacy of Multimodal Thermal Therapy (MTT) Combined With KRAS G12V mRNA Vaccine, S-1, and Sintilimab in Patients With Metastatic Pancreatic Cancer

> **NCT07745790** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Ruijin Hospital** · enrollment: 20 (estimated)

## Conditions studied

- Pancreatic Ductal Adenocarcinoma
- Liver Neoplasms
- Lung Neoplasms

## Interventions

- **DEVICE:** Multimodal Thermal Therapy (MTT) System
- **BIOLOGICAL:** KRAS G12V mRNA Vaccine
- **DRUG:** Sintilimab
- **DRUG:** S-1

## Key facts

- **NCT ID:** NCT07745790
- **Lead sponsor:** Ruijin Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-07-13
- **Primary completion:** 2029-07-31
- **Final completion:** 2029-07-31
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2026-08-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07745790

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07745790, "Safety and Efficacy of Multimodal Thermal Therapy (MTT) Combined With KRAS G12V mRNA Vaccine, S-1, and Sintilimab in Patients With Metastatic Pancreatic Cancer". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07745790. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*